AbbVie Inc. (ABBV) Stake Raised by Whitnell & Co.

Whitnell & Co. lifted its holdings in shares of AbbVie Inc. (NYSE:ABBV) by 6.0% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 51,055 shares of the company’s stock after purchasing an additional 2,908 shares during the period. AbbVie comprises approximately 1.6% of Whitnell & Co.’s investment portfolio, making the stock its 16th largest holding. Whitnell & Co.’s holdings in AbbVie were worth $3,702,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in ABBV. Abner Herrman & Brock LLC increased its holdings in AbbVie by 0.3% in the 2nd quarter. Abner Herrman & Brock LLC now owns 6,293 shares of the company’s stock worth $456,000 after acquiring an additional 18 shares during the last quarter. Bollard Group LLC increased its holdings in AbbVie by 0.5% in the 2nd quarter. Bollard Group LLC now owns 3,764 shares of the company’s stock worth $273,000 after acquiring an additional 19 shares during the last quarter. St. Louis Trust Co increased its holdings in AbbVie by 0.7% in the 1st quarter. St. Louis Trust Co now owns 3,388 shares of the company’s stock worth $221,000 after acquiring an additional 25 shares during the last quarter. Stratford Consulting LLC increased its holdings in AbbVie by 0.7% in the 1st quarter. Stratford Consulting LLC now owns 3,959 shares of the company’s stock worth $258,000 after acquiring an additional 29 shares during the last quarter. Finally, K.J. Harrison & Partners Inc increased its holdings in AbbVie by 0.6% in the 1st quarter. K.J. Harrison & Partners Inc now owns 5,031 shares of the company’s stock worth $328,000 after acquiring an additional 31 shares during the last quarter. Institutional investors own 68.25% of the company’s stock.

Several equities research analysts recently weighed in on ABBV shares. BidaskClub raised AbbVie from a “buy” rating to a “strong-buy” rating in a report on Wednesday, September 6th. Jefferies Group LLC reissued a “buy” rating and issued a $94.00 price objective on shares of AbbVie in a report on Friday, September 8th. Goldman Sachs Group, Inc. (The) reissued a “buy” rating and issued a $100.00 price objective (up previously from $85.00) on shares of AbbVie in a report on Friday, September 8th. Leerink Swann raised AbbVie from a “market perform” rating to an “outperform” rating and lifted their price objective for the stock from $89.00 to $106.00 in a report on Monday, October 2nd. Finally, Zacks Investment Research lowered AbbVie from a “hold” rating to a “sell” rating in a report on Tuesday, July 4th. Seven equities research analysts have rated the stock with a hold rating, twelve have assigned a buy rating and one has issued a strong buy rating to the company. The stock presently has a consensus rating of “Buy” and a consensus price target of $92.79.

In other news, VP Robert A. Michael sold 6,699 shares of AbbVie stock in a transaction that occurred on Thursday, September 28th. The stock was sold at an average price of $88.00, for a total value of $589,512.00. Following the completion of the transaction, the vice president now owns 10,007 shares in the company, valued at approximately $880,616. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, insider Henry O. Gosebruch sold 18,000 shares of AbbVie stock in a transaction that occurred on Monday, July 31st. The stock was sold at an average price of $70.09, for a total value of $1,261,620.00. Following the completion of the transaction, the insider now owns 96,074 shares of the company’s stock, valued at approximately $6,733,826.66. The disclosure for this sale can be found here. In the last quarter, insiders sold 379,890 shares of company stock valued at $27,187,817. Company insiders own 0.23% of the company’s stock.

TRADEMARK VIOLATION NOTICE: This piece of content was first reported by The Ledger Gazette and is the property of of The Ledger Gazette. If you are reading this piece of content on another publication, it was copied illegally and reposted in violation of US and international copyright & trademark law. The original version of this piece of content can be read at https://ledgergazette.com/2017/10/18/abbvie-inc-abbv-stake-raised-by-whitnell-co.html.

Shares of AbbVie Inc. (NYSE ABBV) opened at 92.17 on Wednesday. The company has a market cap of $146.93 billion, a P/E ratio of 22.67 and a beta of 1.51. AbbVie Inc. has a 12 month low of $55.06 and a 12 month high of $92.78. The firm has a 50-day moving average price of $85.49 and a 200 day moving average price of $72.96.

AbbVie (NYSE:ABBV) last announced its earnings results on Friday, July 28th. The company reported $1.42 EPS for the quarter, topping the Zacks’ consensus estimate of $1.40 by $0.02. The firm had revenue of $6.94 billion during the quarter, compared to analysts’ expectations of $6.93 billion. AbbVie had a return on equity of 150.27% and a net margin of 24.77%. The company’s quarterly revenue was up 7.6% on a year-over-year basis. During the same quarter in the previous year, the business earned $1.26 EPS. Equities analysts predict that AbbVie Inc. will post $5.53 earnings per share for the current year.

The business also recently announced a quarterly dividend, which will be paid on Wednesday, November 15th. Stockholders of record on Friday, October 13th will be issued a $0.64 divid

Several other hedge funds and other institutional investors have also added to or reduced their stakes in ABBV. Abner Herrman & Brock LLC increased its holdings in AbbVie by 0.3% in the 2nd quarter. Abner Herrman & Brock LLC now owns 6,293 shares of the company’s stock worth $456,000 after acquiring an additional 18 shares during the last quarter. Bollard Group LLC increased its holdings in AbbVie by 0.5% in the 2nd quarter. Bollard Group LLC now owns 3,764 shares of the company’s stock worth $273,000 after acquiring an additional 19 shares during the last quarter. St. Louis Trust Co increased its holdings in AbbVie by 0.7% in the 1st quarter. St. Louis Trust Co now owns 3,388 shares of the company’s stock worth $221,000 after acquiring an additional 25 shares during the last quarter. Stratford Consulting LLC increased its holdings in AbbVie by 0.7% in the 1st quarter. Stratford Consulting LLC now owns 3,959 shares of the company’s stock worth $258,000 after acquiring an additional 29 shares during the last quarter. Finally, K.J. Harrison & Partners Inc increased its holdings in AbbVie by 0.6% in the 1st quarter. K.J. Harrison & Partners Inc now owns 5,031 shares of the company’s stock worth $328,000 after acquiring an additional 31 shares during the last quarter. Institutional investors own 68.25% of the company’s stock.

Several equities research analysts recently weighed in on ABBV shares. BidaskClub raised AbbVie from a “buy” rating to a “strong-buy” rating in a report on Wednesday, September 6th. Jefferies Group LLC reissued a “buy” rating and issued a $94.00 price objective on shares of AbbVie in a report on Friday, September 8th. Goldman Sachs Group, Inc. (The) reissued a “buy” rating and issued a $100.00 price objective (up previously from $85.00) on shares of AbbVie in a report on Friday, September 8th. Leerink Swann raised AbbVie from a “market perform” rating to an “outperform” rating and lifted their price objective for the stock from $89.00 to $106.00 in a report on Monday, October 2nd. Finally, Zacks Investment Research lowered AbbVie from a “hold” rating to a “sell” rating in a report on Tuesday, July 4th. Seven equities research analysts have rated the stock with a hold rating, twelve have assigned a buy rating and one has issued a strong buy rating to the company. The stock presently has a consensus rating of “Buy” and a consensus price target of $92.79.

In other news, VP Robert A. Michael sold 6,699 shares of AbbVie stock in a transaction that occurred on Thursday, September 28th. The stock was sold at an average price of $88.00, for a total value of $589,512.00. Following the completion of the transaction, the vice president now owns 10,007 shares in the company, valued at approximately $880,616. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, insider Henry O. Gosebruch sold 18,000 shares of AbbVie stock in a transaction that occurred on Monday, July 31st. The stock was sold at an average price of $70.09, for a total value of $1,261,620.00. Following the completion of the transaction, the insider now owns 96,074 shares of the company’s stock, valued at approximately $6,733,826.66. The disclosure for this sale can be found here. In the last quarter, insiders sold 379,890 shares of company stock valued at $27,187,817. Company insiders own 0.23% of the company’s stock.

TRADEMARK VIOLATION NOTICE: This piece of content was first reported by The Ledger Gazette and is the property of of The Ledger Gazette. If you are reading this piece of content on another publication, it was copied illegally and reposted in violation of US and international copyright & trademark law. The original version of this piece of content can be read at https://ledgergazette.com/2017/10/18/abbvie-inc-abbv-stake-raised-by-whitnell-co.html.

Shares of AbbVie Inc. (NYSE ABBV) opened at 92.17 on Wednesday. The company has a market cap of $146.93 billion, a P/E ratio of 22.67 and a beta of 1.51. AbbVie Inc. has a 12 month low of $55.06 and a 12 month high of $92.78. The firm has a 50-day moving average price of $85.49 and a 200 day moving average price of $72.96.

AbbVie (NYSE:ABBV) last announced its earnings results on Friday, July 28th. The company reported $1.42 EPS for the quarter, topping the Zacks’ consensus estimate of $1.40 by $0.02. The firm had revenue of $6.94 billion during the quarter, compared to analysts’ expectations of $6.93 billion. AbbVie had a return on equity of 150.27% and a net margin of 24.77%. The company’s quarterly revenue was up 7.6% on a year-over-year basis. During the same quarter in the previous year, the business earned $1.26 EPS. Equities analysts predict that AbbVie Inc. will post $5.53 earnings per share for the current year.

The business also recently announced a quarterly dividend, which will be paid on Wednesday, November 15th. Stockholders of record on Friday, October 13th will be issued a $0.64 dividend. This represents a $2.56 dividend on an annualized basis and a dividend yield of 2.78%. The ex-dividend date of this dividend is Thursday, October 12th. AbbVie’s dividend payout ratio (DPR) is 62.90%.

About AbbVie

AbbVie Inc (AbbVie) is a research-based biopharmaceutical company. The Company is engaged in the discovery, development, manufacture and sale of a range of pharmaceutical products. Its products are focused on treating conditions, such as chronic autoimmune diseases in rheumatology, gastroenterology and dermatology; oncology, including blood cancers; virology, including hepatitis C virus (HCV) and human immunodeficiency virus (HIV); neurological disorders, such as Parkinson’s disease and multiple sclerosis; metabolic diseases, including thyroid disease and complications associated with cystic fibrosis, and other serious health conditions.

Institutional Ownership by Quarter for AbbVie (NYSE:ABBV)

Receive News & Ratings for AbbVie Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply